J Clin Microbiol 2004, 42:5364–5367.CrossRefPubMed 34. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H: Randomised controlled trial of two-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997, 350:1569–1577.CrossRefPubMed 35. Berg BM, Beekhuizen H, Willems RJ, Mooi FR, van Furth R: Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. Infect Immun 1999, 67:1056–1062.PubMed 36. Wilkie BN: Respiratory tract immune response SN-38 solubility dmso to microbial pathogens. J Am Vet

Med Assoc 1982, 181:1074–1079.PubMed 37. Robinson A, Gorringe AR, Funnell SG, Fernandez M: Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 1989, 7:321–324.CrossRefPubMed 38. Zhang H, Zhang S, Zhuang H, Lu F: CytotoxiCity of a Novel Fibroblast Growth Factor Receptor Targeted Immunotoxin on Human Ovarian Teraocarcinoma Cell Line. Cancer Biother Radiopharm 2006, 21:321–332.CrossRefPubMed 39. Towbin H, Staehlin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure

and some applications. Proc Natl Acad Sci 1979, 76:4350–4354.CrossRefPubMed 40. Hou QM, Zhang SM, Tian B, Liang YW, Zhang LM, Xiang MJ, Huang ZL: Development of the fifth national standard preparation for pertussis vaccine potency assay. Chin J Biol Y-27632 chemical structure 2004, 06:393–396. Competing interests The authors declare that they have no competing interests. Authors’ contributions SZ and YX conceived the study. SZ, YX, and YW designed the experiments. YX, YW, LJW, LW and QH performed the molecular biological work and the

animal studies. YT and HZ performed the statistical analyses and prepared the figures. YX and YW wrote the draft of the manuscript. SZ, YT, and HZ revised the manuscript. All authors read and approved the final version of the manuscript.”
“Background In the last 25 years, Escherichia coli serogroup O157 (E. coli O157) has become an important cause of severe gastrointestinal illness in westernised countries, warranting substantial public health concern. Clinical Aspartate signs range from mild diarrhoea to haemorrhagic colitis and haemolytic uraemic syndrome (HUS) which may result in death [1]. HUS usually occurs in young children and is the major cause of acute renal failure in children in western countries [2]. Clinical surveillance in Scotland has shown that over 90% of HUS cases are associated with E. coli O157 infection [3]; similar observations have been made in other countries [4–6]. Cattle are the main reservoir for E. coli O157 [7], and play a major role in the epidemiology of human infections [8]. Visits to farms, contact with animal excreta and recreational use of animal pasture have all been identified as Dasatinib significant risk factors for sporadic human infections [9–12].